Publications

2019

Gomez-Arteaga A, Margolskee E, Wei MT, Van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019;60(7):1626-1631.
Hwang JH, Seo J-, Beshiri ML, Wankowicz S, Liu D, Cheung A, et al. CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. Cell Rep. 2019;29(8):2355-2370.e6.
Kobayashi S, Contractor T, Vosburgh E, Du Y-, Tang LH, Clausen R, et al. Alleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumors. Oncogenesis. 2019;8(3):16.
Gaffney C, Golan R, Cantu MD, Scognamiglio T, McCarthy H, Mosquera JM, et al. The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer. J Urol. 2019;202(1):96-101.
Schatz-Siemers N, Brandler TC, Oweity T, Sun W, Hernandez A, Levine P. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation. Diagn Cytopathol. 2019;47(10):977-985.
Clijsters L, Hoencamp C, Calis JJ, Marzio A, Handgraaf SM, Cuitiño MC, et al. Cyclin F Controls Cell-Cycle Transcriptional Outputs by Directing the Degradation of the Three Activator E2Fs. Mol Cell. 2019;74(6):1264-1277.e7.
Schwartz GW, Manning B, Zhou Y, Velu P, Bigdeli A, Astles R, et al. Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors. Clin Cancer Res. 2019;25(2):573-583.
Glynn S, Lipkin S, Zhang T, Sboner A, Elemento O, Van Besien K, et al. The application of precision medicine in diagnosing familial Mediterranean fever. Leuk Lymphoma. 2019;60(8):2091-2093.
Solomon JP, Hechtman JF. Detection of Fusions: Merits and Limitations of Current Diagnostic Platforms. Cancer Res. 2019;79(13):3163-3168.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700